Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “overweight” rating reissued by stock analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday.

Several other analysts have also recently issued reports on the stock. Jefferies Group decreased their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,500 ($30.97) to GBX 2,000 ($24.77) and set a “buy” rating on the stock in a research report on Friday. Numis Securities Ltd restated a “buy” rating and set a GBX 2,350 ($29.11) target price on shares of Hikma Pharmaceuticals Plc in a research report on Thursday. Barclays PLC restated an “overweight” rating and set a GBX 2,900 ($35.92) target price on shares of Hikma Pharmaceuticals Plc in a research report on Friday, September 9th. Morgan Stanley decreased their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,700 ($33.44) to GBX 2,500 ($30.97) and set an “equal weight” rating on the stock in a research report on Friday, August 12th. Finally, Citigroup Inc. cut shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.21) target price on the stock. in a research report on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of GBX 2,367.40 ($29.32).

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1628.00 on Friday. The stock’s market capitalization is GBX 3.68 billion. The firm has a 50-day moving average of GBX 1,924.84 and a 200 day moving average of GBX 2,214.14. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00.

In related news, insider Said Darwazah bought 50,000 shares of the company’s stock in a transaction on Monday, September 26th. The shares were acquired at an average cost of GBX 2,078 ($25.74) per share, for a total transaction of £1,039,000 ($1,287,006.07). Also, insider Darwazah,Mazen bought 155,991 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was bought at an average price of GBX 2,194 ($27.18) per share, for a total transaction of £3,422,442.54 ($4,239,368.93).

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.